---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-016981"
form_type: "8-K"
ticker: "MNPR"
cik: "0001645469"
company_name: "Monopar Therapeutics"
filed_at: "2026-05-14T18:00:13+00:00"
generated_at: "2026-05-14T18:02:20.893276+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monopar Therapeutics Q1 2026 net loss $3.9M; NDA on track for mid-2026

## Summary
- Net loss $3.9M ($0.46/share) in Q1 2026 vs $2.6M ($0.38/share) in Q1 2025.
- Cash equivalents and investments $137.5M; expects funding through Dec 2027.
- NDA for ALXN1840 (Wilson disease) on track for FDA submission in mid-2026.
- R&D expenses $3.49M, up $1.84M YoY due to contractor/consulting and personnel.
- Presented at AAN; upcoming at EAN (June 27-30) and EASL Congress (May 27-30).

## SEC filing metadata
- accession: 0001437749-26-016981
- form_type: 8-K
- ticker: MNPR
- cik: 0001645469
- company_name: Monopar Therapeutics
- filed_at: 2026-05-14T18:00:13+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645469/000143774926016981/0001437749-26-016981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645469/000143774926016981/mnpr20260513c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-016981
- JSON: https://secwatch.observer/filing/0001437749-26-016981.json
- Plain text: https://secwatch.observer/filing/0001437749-26-016981.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.